Publications
My scientific training shaped how I think: define the problem clearly, evaluate evidence carefully, challenge assumptions, and communicate complex findings in a way others can use.
Before moving into biotechnology operations and executive leadership, my research focused on human B-cell responses to pneumococcal vaccination, including work involving HIV-positive and elderly populations. That foundation in immunology, clinical research, assay development, and translational science continues to inform how I evaluate risk, opportunity, and organizational decisions.
Why it matters: Characterized human B-cell responses to pneumococcal polysaccharide vaccination and helped clarify early immune-response phenotypes.
Why it matters: Identified age-related differences in pneumococcal polysaccharide vaccine response, with implications for high-risk populations.
Why it matters: Examined human polyreactive pneumococcal polysaccharide antibodies and the relationship between antibody structure, isotype, avidity, and specificity.
Why it matters: Used flow cytometry to characterize pneumococcal polysaccharide-specific B cells and clarify the role of IgM memory cells in vaccine response.